Author: sofia

By: Caitlin A. Koppenhaver, Attorney with Florida Healthcare Law Firm and Chief Industry Advisor to APA

There is a persistent tendency in healthcare policy discussions to treat compounding as though it is uniquely tied to quality and safety risk, while assuming conventional manufacturing occupies a separate and superior category. That is not a constructive way to think about patient safety.

FDA’s March 5, 2026 warning letter to Novo Nordisk is a useful reminder that compliance risk is not confined to compounders or to any single segment of the market. In this case, FDA cited serious violations relating to postmarketing adverse drug experience (PADE) reporting, including deficiencies in written procedures, failures to report certain serious and unexpected adverse drug experiences to FDA within required timeframes, and deficiencies in quality control oversight of contractors performing delegated pharmacovigilance functions.

The takeaway should not be to diminish the importance of oversight in any setting. It should be to reinforce a more balanced principle that quality is a systems issue, not a categorical label. Pharmacies engaged in patient-specific compounding serve an important function, especially where individualized medication needs cannot be met by commercially available products. At the same time, manufacturers, outsourcing facilities, pharmacies, and others involved in the drug supply chain remain responsible for building and maintaining compliant, reliable quality systems.

For those of us who work in and around this space, the better conversation is not whether one sector is inherently “safe” and another is inherently “suspect.” The better conversation is whether the entity in question is operating with the level of rigor, documentation, oversight, and accountability that patient safety demands. FDA’s letter is a reminder that no segment of the industry is exempt from that responsibility.

Reference: FdaNovo Nordisk Inc. – 717576 – 03/05/2026

By: Caitlin A. Koppenhaver, Attorney with Florida Healthcare Law Firm and Chief Industry Advisor to APA

FDA’s announcement regarding the launch of AEMS is worth watching. The Adverse Event Monitoring System is intended to consolidate multiple reporting systems across FDA-regulated product categories into a single platform, including medical products, vaccines, devices, tobacco, food, cosmetics, and veterinary products.

Legacy systems to be replaced by AEMS now include:

FAERS (FDA Adverse Event Reporting System) — containing reports for drugs, biologics, cosmetic products, and color additives.

VAERS (Vaccine Adverse Event Reporting System) — containing reports for vaccines. Note: The FDA will display VAERS data in AEMS. VAERS is co-managed by the FDA and Centers for Disease Control and Prevention.

AERS (Adverse Event Reporting System) — two databases containing reports for animal drugs and animal foods.

Legacy systems to be replaced by AEMS in May 2026 include:

MAUDE (Manufacturer and User Facility Device Experience) — containing reports for medical devices.

HFCS (Human Foods Complaint System) — containing reports for human foods and dietary supplements.

CTPAE (Center for Tobacco Products Adverse Event Reporting System) — containing reports for Electronic Nicotine Delivery Systems (ENDS) and other tobacco products.

More than a technology update, AEMS reflects an effort to improve data quality and consistency, streamline reporting, reduce administrative burden, and strengthen FDA’s ability to monitor trends across product categories through enhanced analytics and more integrated review tools.

FDA also indicated that the platform will support not only adverse event reporting, but also consumer complaints, regulatory misconduct reports, and whistleblower submissions. The broader takeaway is that postmarket oversight depends heavily on infrastructure, and systems like this can directly affect how efficiently concerns are identified, evaluated, and addressed.

Article: LinkedinThe FDA is transforming how we monitor product safety. Beginning today, the new Adverse Eve…

By: Caitlin A. Koppenhaver

A clip from HHS Secretary Robert F. Kennedy Jr.’s recent Joe Rogan Experience appearance has been making the rounds in the peptide and broader wellness industries. The headline is Kennedy said he wants to move about fourteen peptides that are currently treated as “Category 2” back into “Category 1,” and he framed the original move into Category 2 as being not supported by an actual safety risk.

The Regulatory Buzz around Category 2

That point is exciting and controversial as “Category 2” has historically functioned in clinical and pharmacy practice like a scarlet letter. It’s the bucket FDA has used to communicate that certain bulk drug substances present “significant safety risks” when used in human drug compounding, and, even when prescribed or dispensed under a legitimate provider-patient relationship with regulated quality sourcing, have still been grounds for state board disciplinary action. When peptides land there, regulated clinical access gets squeezed, compounding partners get nervous because they are at risk for dispensing them, clinics get increasingly cautious to prescribe them, and everyone starts asking whether it’s even worth touching, even with the meaningful and demonstrated positive patient impacts that providers and pharmacies have witnessed in patient care.

When Regulatory Supply Shrinks, Demand Doesn’t Disappear

Kennedy’s thesis was essentially that if there wasn’t a real safety signal that warranted the restriction in the first place, then keeping these peptides in Category 2 doesn’t actually protect patients, but it just pushes demand into places that are harder to supervise from a regulatory and quality standpoint. He said the black market opened up, and he wants to do something about it.

A lot of policymakers significantly underestimate this part, though most operators understand it instinctively. If you remove regulated supply without removing demand, you don’t get “less use”. People don’t wait for regulators to change their minds. Instead, you get different and inconsistent channels. Patients don’t stop searching. Clinicians don’t stop getting asked about them. The only thing that changes is whether access flows through inspected, accountable infrastructure or through workarounds with minimal oversight and unclear incentives.

If these peptides really do move back into Category 1, it would reroute access for many back toward licensed clinical decision-making, medical records, pharmacy controls, quality systems, and regulated product traceability. It also changes consumer behavior in a way people aren’t talking about enough. A lot of RUO demand is not ideological. It’s logistical. When something isn’t available through normal clinical channels, consumers drift into self-directed purchasing and reconstitution. But when that same therapy becomes accessible again through telehealth and clinic models, where there’s dosing guidance, monitoring, and continuity of care, a meaningful segment will pivot back. Not because people suddenly became compliance purists, but because most people would rather not guess if there is an option for clinical guidance. That said, it’s still not a universal swing back. Another meaningful subset of the public has also lost faith in traditional clinical leadership, cannot find enough providers who are knowledgeable enough in the wellness space, and others simply don’t want to pay for clinical guidance or deal with insurance companies on top of supply costs, so access will still fragment across channels even if “Category 1” availability expands.

What we still don’t have, though, is the part everyone wants most: which peptides, when, and through what formal FDA action. Until there’s something in writing from FDA, anyone claiming to have “the list” is either speculating or selling something.

Quality and Accountability Will Continue to Matter Most Regardless of the Delivery Platform

Even if regulated clinical pathways expand, consumer-facing models may still exist, but the long term winners will be the channels that can demonstrate sourcing integrity, transparency, and appropriate quality guardrails, and that invest in sustainable, differentiating product and manufacturing safety measures.

And even if the reclassification happens, the work doesn’t end there. Moving a substance back into a more permissive bucket doesn’t eliminate quality risk, but it actually raises the stakes. More access means more volume, more attention, more patient exposure, and more scrutiny. Manufacturers, compounders, clinics, and third-party platforms should treat this moment as a prompt to tighten, not loosen, quality systems, supplier qualification, documentation, complaint handling, and marketing discipline.

If we want a world where the public can access these therapies safely, this is what it looks like: consistent and streamlined channels that can be audited, inspected, and held accountable. If Kennedy is right that there wasn’t a real safety basis for the Category 2 posture of these peptides, then correcting that posture is not a ‘gift to the industry,’ but a course correction that recognizes these peptides are not as dangerous as they’ve been positioned—when used correctly.

By: Caitlin A. Koppenhaver

Florida’s HB 1429 (and Senate companion SB 1728) is one of the clearest messages to date that Florida is preparing to regulate medical spas offering prescription medications, including weight loss drugs and biological products, under a more formal, pharmacy-adjacent framework. The bills would create the “Medical Spa Prescription Drug Oversight Act” and move certain medical spa operations under direct oversight by the Florida Board of Pharmacy, which would effectively allow the Board or approved third parties to conduct onsite inspections.

The Legislature’s starting point is direct: “The Legislature finds that patients are increasingly turning to medical spas for cosmetic and medical procedures. Many of these medical spas prepare and administer prescription medications intended to be sterile, either compounded or commercially available formulations, with no regulatory oversight by the Board of Pharmacy, which raises significant patient safety concerns”. The bill treats that perceived gap as a regulatory problem that needs to be closed. In other words, Florida is treating the outpatient service line where drugs are marketed, stored, handled, and administered, as part of the regulated prescription drug chain.  Medspas are not currently licensed and certainly not required to have anything like a pharmacy license!

What the bill does

HB 1429 would require each medical spa location that “prepares, handles, stores, administers, dispenses, distributes, or otherwise uses” prescription medication at the facility or in connection with providing services to obtain and maintain a license from the Board of Pharmacy. The definition of “medical spa” is drafted to capture modern wellness and longevity models and explicitly includes weight loss services, botulinum toxin injections, hormone therapies, and parenteral nutrient therapies.

“Medical spa” means any facility or practice that offers medical or health care services and that holds itself out as a facility or practice focused on cosmetic or lifestyle treatments, such as weight loss, wellness, longevity, or cosmetic or aesthetic health care services, including, but not limited to, the preparation, administration, or dispensing of prescription drugs for weight loss; botulinum toxin injections; hormone therapies; or parenteral nutrient therapies. The term does not include a facility or practice that otherwise holds a health care facility license from the state.”

The bill is also not just focused on GLP-1’s, as the bill defines a “Prescription medication” to include any drug, including, but not limited to, finished dosage forms or active ingredients that are subject to, defined in, or described in section. 503(b) of the Federal Food, Drug, and Cosmetic Act (which regulates outsourcing facilities) or in certain provisions of the Florida Pharmacy Practice Act and the Florida Drug and Cosmetic Act. The term also includes “any biological product, except for blood and blood components intended for transfusion or biological products that are also medical devices”. 

The proposal also states that a licensed medical spa is treated as a “dispenser” under federal law and must comply with federal supply chain requirements. That provision is a tell:  the bill is not merely about licensure; it is about importing pharmaceutical supply-chain discipline into the med-spa environment, meaning tighter expectations around sourcing, handling, documentation, and accountability. 

If enacted, failure to obtain a license or comply with any requirements may result in disciplinary action by the Florida Board of Pharmacy,  including, but not limited to, fines, suspension, or revocation of the license. The Florida Board of Pharmacy will also maintain a public database of each medical spa licensed in Florida, which will include at a minimum, the name, address, and license number of each medical spa and the name and license number of the responsible person, who must be physically present at the medspa location “for a sufficient amount of time to perform his or her responsibilities”, which includes confirming compliance with the bill’s requirements.

The bigger picture for the peptide and wellness space

Zooming out, HB 1429/SB 1728 fits a broader pattern of Big Pharma infiltrating the wellness space, especially to suppress compounded GLP competition.  Regulators are increasingly looking beyond the compounding site and focusing on the outpatient endpoint where high-demand therapies, particularly GLP-1 weight loss drugs and other peptide offerings, are marketed and administered.  Even when a pharmacy is the dispenser, the consumer-facing platform (often the medical spa) is where risks tend to surface: how the program is marketed, how intake and payment flow are structured, what happens on-site, and how adverse outcomes are handled. Florida’s approach reflects a growing view that compounding oversight, consumer-facing promotion, and outpatient administration are part of one continuous risk chain.

That’s also why the bill includes a consumer protection enforcement provision that directly implicates common GLP-1 marketing practices. The bill ties certain misrepresentations about prescription medications to Florida’s Deceptive and Unfair Trade Practices Act, including the medical spa “misrepresenting a prescription medication as having”:

• A particular standard, quality, or grade;
• Sponsorship, approval, characteristics, ingredients, uses, or benefits;
• A function similar to a drug approved by the federal Food and Drug Administration; or
• Approval from the federal Food and Drug Administration.

For weight loss programs, that language reads as a warning shot at equivalency-style messaging and FDA-adjacent phrasing. This is also one of the first states we have seen include a focus specifically on marketing, as typically the FDA and FTC will focus on marketing enforcement.  The bill changes the entire character of a medspa to a highly regulated environment and will likely cause many Medspas to rethink their commitment to GLP weight loss programs.  And the bill goes further than that by expanding its pharma net to products like Botox.   Why is that?  Is this going to save lives?  What problem is being fixed here?  The proposed law seeks to regulate with no apparent precision and somewhat brutalizing an entire industry. 

Comments to Common Questions

Likelihood of passage

It’s too early in the 2026 session to speak in certainties, but the bill is moving in both chambers with companion legislation. Companion bills filed early and routed through committee are often a sign the concept has meaningful traction, even if details evolve through amendments and stakeholder input.  Where exactly are the stakeholders in this process?  Has any Medspa at all been consulted re the presumptions riddled through this bill?

Timing/effective date

If passed, SB 1728 lists an effective date of July 1, 2026, while HB 1429 is drafted to take effect upon becoming law.  There is not reasonable opportunity to prepare to even to get rid of perhaps a large supply of affected product.  HB 1429 also directs the Board to adopt implementing rules within six months after the section takes effect, which suggests a buildout period for the application process and enforcement infrastructure. The practical takeaway is that the “real” compliance protocols will likely be driven by how quickly the Board stands up rules and applications, but businesses should plan as if expectations could move quickly once enacted.

Licensing Implications

The core mechanism is a new Board of Pharmacy license requirement for medical spas that handle prescription medications as described in the trigger language. The bill also contemplates a public database of licensed medical spas and the designated “responsible person,” which reinforces that Florida intends visibility and accountability at the facility level, not just a get it and forget it registration.

Proactive steps

While the bill is still proposed, the most efficient preparation is internal clarity. Medspas should review the bill closely and confirm whether the current workflow triggers licensure based on how prescription products are sourced, stored, and administered at the facility or “in connection with” services, and pressure-test marketing and patient-facing materials for any equivalency or FDA-adjacent messaging that could create exposure under the consumer protection provision. 

Bottom line

As we previously reported about Indiana’s medspa bill introduced in January, HB 1429/SB 1728 is Florida’s attempt to regulate medical spas offering prescription medications—particularly in consumer-facing wellness and weight loss models—by treating those settings as part of the prescription drug oversight ecosystem. If you’re operating in the GLP-1/weight loss lane, this is a bill to watch closely, because it targets the delivery model—not just the drug.  Cast in its worst light, any business that utilizes a product that compete with Pharma GLPs can expect similar overregulation and disregard for rational or demonstrable justification. 

By: Caitlin A. Koppenhaver

If you felt like the compounded oral semaglutide headlines were changing by the hour, you weren’t imagining it. Within days, the narrative shifted from a consumer-facing launch to heightened FDA attention and legal escalation, ending with a rapid withdrawal.

How This Unfolded—Fast

On Thursday, February 5, Hims & Hers announced it was expanding its weight-loss portfolio with access to compounded semaglutide pills, promoted as having “the same active ingredient as Wegovy®”, and marketed with introductory pricing starting at $49 (with pricing that varies by plan). The announcement immediately landed in the middle of the broader “compounded GLP-1” conversation, namely, whether these offerings fit within narrow, patient-specific compounding exceptions permitted under the Federal Food, Drug, and Cosmetic Act (FDCA), or whether they were being positioned as scaled substitutes for FDA-approved products, which is where FDA scrutiny and branded manufacturer enforcement tend to converge.

That same day, Novo Nordisk’s CEO publicly questioned whether a compounded oral semaglutide pill would work as consumers expect, reportedly describing it as a “waste of money” because it lacks the SNAC absorption technology used in Novo’s FDA-approved oral Wegovy formulation. “SNAC” is a proprietary excipient that helps semaglutide survive the stomach and be absorbed into the bloodstream when taken orally. Without it, semaglutide is largely degraded by stomach acid and enzymes, meaning the active peptide may not reach the bloodstream in meaningful amounts. Novo’s point,  anchored in its public comments at an investor meeting on Feb. 5, 2026, is that an oral semaglutide pill without this type of enhancer is unlikely to perform clinically like an FDA-approved product.

By Friday, February 6, the FDA publicly escalated its position. In a formal statement, the agency said it intends to “take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies — including Hims & Hers and other compounding pharmacies — as similar alternatives to FDA-approved drugs”. The action was framed around consumer protection and the agency’s inability to verify quality, safety, or efficacy for compounded formulations. 

The business impact was almost immediate. On Saturday, February 7, reporting confirmed Hims stopped offering access to the compounded semaglutide pill after what it described as “constructive conversations with stakeholders across the industry”, in the wake of FDA’s statements and the broader regulatory scrutiny.

And on Monday, February 9, Novo Nordisk formally escalated to litigation, filing suit against Hims & Hers alleging patent infringement tied to compounded semaglutide products and seeking injunctive relief and damages. As stated by their CEO, “Novo Nordisk is asking the court to permanently ban Hims from selling unapproved, compounded drugs that infringe our patents, and is seeking to recover damages”.

One point worth flagging, because it helps explain the speed of the escalation, is how Novo framed the moment. In public comments, Novo suggested Hims was the “tipping point,” in the sense that a highly visible, consumer-facing rollout drew immediate attention and prompted a faster, more public response. 

What This Means for Industry Participants

While this week in no way settled the compounded GLP-1 debate, it did, however, show how quickly the conversation can accelerate when FDA signaling and branded manufacturer enforcement converge in a high-demand category. It also highlights a few practical realities compounding pharmacies and their partners should keep in mind right now.

For compounders, the risk often turns on posture and messaging: tightly patient-specific, pharmacy-controlled dispensing tends to be viewed differently than marketing that reads like a substitute for an FDA-approved drug.

For telehealth platforms, scale and consumer marketing amplify everything. Even if a licensed pharmacy is dispensing, a national rollout can draw immediate attention from regulators and brand manufacturers.

And for both, transparency matters, not just from an FDA standpoint. From an FTC risk standpoint, regulators look at the overall takeaway a reasonable consumer would get from the ad, not just whether each sentence is technically defensible. If the headline, pricing, visuals, or phrasing leaves consumers thinking “FDA-approved” or “equivalent to Wegovy,” disclaimers buried later may not cure the overall net impression. 

By: Caitlin A. Koppenhaver

Indiana Senate Bill 282 (SB 282), introduced January 12, 2026, is a combined proposal aimed at two parts of the market regulators increasingly treat as one continuous risk chain: (i) compounded-drug sourcing and documentation and (ii) outpatient medical spa delivery models offering injectable products. If enacted in anything close to its introduced form, SB 282 would tighten expectations for bulk drug substance use, impose rapid record-production timelines, require semiannual state reporting on compounding risks (including marketing/telehealth-related categories), and create a Board of Pharmacy registration and oversight regime for medical spas beginning January 1, 2027.  It will be the first time we’re aware of that any state has required a MedSpa to obtain pharmacy license for just selling peptides. 

What SB 282 is really doing

SB 282 is not just “a pharmacy bill” and not just “a medspa bill.” It is an attempt to regulate the outpatient ecosystem where compounded drugs (including peptides) are promoted, distributed, and administered. The bill directs the Indiana Department of Health to publish semiannual reports on compounding oversight and risks and indicates that the state is looking beyond the compounding site itself, reaching retail/outpatient settings that handle, store, administer, dispense, distribute, or use compounded drugs, including 503A pharmacies, 503B outsourcing facilities, and medical spas.

That same reporting mandate explicitly contemplates disciplinary actions relating to improper marketing, advertising, or promotion of compounding drugs and telehealth services. Indiana is framing patient safety and “consumer-facing” promotion as inseparable from compounding oversight.

Why compounding pharmacies and suppliers should care

SB 282 creates a new Indiana Code chapter titled “Drugs: Restrictions on Bulk Drug Substances.” It defines “compounding” broadly (including mixing, diluting, pooling, reconstituting, or otherwise altering a drug or bulk drug substance) and then states a person may not engage in compounding unless specified requirements are met. Those requirements include USP/NF monograph and USP chapter-related criteria where applicable, pharmaceutical grade expectations, and documentation expectations such as certificates of analysis with specified content.  Given the popularity of peptides and the movement of MedSpas into the wellness space, the Bill is a clear shot by Pharma into compounded competition.  It essentially knocks MedSpas out of the peptide space. 

One introduced provision is likely to draw intense scrutiny if it remains: the bill requires that “any bulk drug substance used has been reviewed as part of a new drug application and approved” under 21 U.S.C. § 355. Whether that language is amended later or not, its inclusion reflects legislative appetite to narrow what ingredients may be treated as acceptable for compounding in Indiana.

Just as important operationally, SB 282 is drafted to accelerate oversight. The bill imposes recordkeeping and production obligations with a short fuse. It requires covered parties to furnish specified records to the Indiana Board of Pharmacy not later than one business day after receipt of a request, unless the Board indicates a reasonable alternative timeframe; it also includes a parallel obligation for a person that engages in compounding to provide records within one business day or a Board-determined reasonable time.

A key precision point for industry: this obligation is not framed as “pharmacies only.” The introduced text uses “any person” in the sale/transfer/distribution recordkeeping provision and separately addresses “a person that engages in compounding.” That drafting choice increases the likelihood that Indiana could apply documentation expectations broadly across the outpatient chain, depending on enforcement posture and final statutory language.

Why medical spas and wellness clinics should care

SB 282 defines “medical spa” in a way that captures many modern wellness and longevity models, not just facility that calls itself a “MedSpa.”  “A facility or practice that provides medical healthcare services, uses prescription drugs for IV/IM/subcutaneous delivery, and holds itself out as focused on cosmetic or lifestyle treatments (including weight loss, wellness, and longevity)”, with examples such as botulinum toxin injections, hormone therapies, and parenteral nutrient therapies.

Under the proposed law, beginning January 1, 2027, medical spas must be registered with the Indiana Board of Pharmacy to do business in Indiana, and the Board must maintain a public database of registration information and disciplinary actions (with redaction of certain health information). The bill also requires each medical spa to designate a “responsible person” who must be physically present for sufficient time to ensure compliance with the bill.

SB 282 further requires reporting to the Board of “serious adverse events” not later than five days after occurrence, with specified information including the prescription medication involved and relevant medical records. For operators, this is a concrete shift away from loosely governed “provider network” models and toward a named-accountability framework with mandatory incident reporting.

Key Takeaways

Stakeholders may consider reviewing bulk drug substance sourcing and documentation narratives, assessing whether records could realistically be produced within a one-business-day timeframe, and evaluating whether outpatient partners, particularly medical spas and wellness clinics, are structured to withstand Board-level registration, accountability, and adverse-event reporting requirements.  At a minimum, businesses operating in or supplying Indiana should closely monitor SB 282 as it moves through committee review and amendment. The most consequential language, definitions, ingredient criteria, and enforcement hooks, often evolves during that process, and early awareness provides the best opportunity to anticipate compliance shifts before they become binding obligations.

SB 282 is proposed legislation, but if passed it would further cement the state’s clear alignment with the pharmaceutical industry.  Like the state’s proposed Safe Act” (a/k/a “Lilly’s Law”), Indiana’s full commitment to protecting Pharma’s compounded GLP market share couldn’t be more transparent, even at the cost of access and affordability.  Make no mistake:  the latest Indiana proposed law is pure economic protectionism.  And it cares not for its impact on price or access. 

The real question is how far Indiana will go to embrace its Pharma overlords.  The first step (Safe Act) essentially puts the compound pharmacy industry out of business vis a vis the GLP market.  This latest proposed law now aims directly at wellness based businesses that use compounded GLPs to help their wellness clients.